bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 3,522 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $173.61, for a total transaction of $611,454.42. Following the transaction, the insider now directly owns 13,959 shares in the company, valued at approximately $2,423,421.99. The transaction was disclosed in a filing with the SEC, which is available through this link.
David Davidson also recently made the following trade(s):
- On Wednesday, January 3rd, David Davidson sold 6,000 shares of bluebird bio stock. The stock was sold at an average price of $180.30, for a total transaction of $1,081,800.00.
bluebird bio Inc (NASDAQ BLUE) traded down $6.35 during trading on Friday, hitting $198.90. 785,957 shares of the company’s stock traded hands, compared to its average volume of 878,787. bluebird bio Inc has a 1 year low of $71.25 and a 1 year high of $222.03. The company has a market cap of $8,830.00, a PE ratio of -28.37 and a beta of 2.07.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. During the same period in the prior year, the business earned ($2.07) EPS. bluebird bio’s quarterly revenue was up 397.4% compared to the same quarter last year. research analysts anticipate that bluebird bio Inc will post -6.71 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. American Century Companies Inc. increased its stake in shares of bluebird bio by 3.2% during the 4th quarter. American Century Companies Inc. now owns 234,220 shares of the biotechnology company’s stock worth $41,715,000 after purchasing an additional 7,285 shares during the last quarter. Meeder Asset Management Inc. increased its stake in shares of bluebird bio by 2,110.3% during the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 612 shares during the last quarter. CIBC Asset Management Inc purchased a new stake in shares of bluebird bio during the 4th quarter worth approximately $247,000. Aperio Group LLC increased its stake in shares of bluebird bio by 22.6% during the 4th quarter. Aperio Group LLC now owns 6,496 shares of the biotechnology company’s stock worth $1,157,000 after purchasing an additional 1,197 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of bluebird bio during the 4th quarter worth approximately $1,225,000.
BLUE has been the topic of a number of research analyst reports. Goldman Sachs Group reissued a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a research report on Friday, October 6th. Leerink Swann reissued an “outperform” rating and set a $145.00 price objective (up previously from $120.00) on shares of bluebird bio in a research report on Friday, October 6th. Maxim Group reissued a “buy” rating and set a $170.00 price objective (up previously from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Jefferies Group reaffirmed a “hold” rating and issued a $126.00 price target on shares of bluebird bio in a research report on Wednesday, October 11th. Finally, Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target on the stock in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. bluebird bio has a consensus rating of “Hold” and a consensus price target of $161.45.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/03/insider-selling-bluebird-bio-inc-blue-insider-sells-611454-42-in-stock.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.